Clomipramine enhances prolactin and growth hormone responses to L-tryptophan.
The effects of the 5-hydroxytryptamine (5-HT) uptake inhibitor clomipramine on the prolactin (PRL) and growth hormone (GH) responses to L-tryptophan (LTP) were assessed in six normal subjects. Oral administration of 20 mg clomipramine 2 h prior to LTP infusion (50 mg/kg) significantly enhanced both endocrine responses, suggesting that the increases in plasma PRL and GH produced by LTP are mediated by 5-HT pathways. These findings, taken together with previous observations that 5-HT2 receptor antagonists do not attenuate the PRL response to LTP, suggest that the 5-HT-induced release of PRL in man may be mediated by 5-HT1 receptors.
D000328:Adult; D001921:Brain / Q000187:drug effects*; D002997:Clomipramine / Q000008:administration & dosage*; D004357:Drug Synergism; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009434:Neural Pathways / Q000187:drug effects; D011388:Prolactin / Q000097:blood*; D012701:Serotonin / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects; D014364:Tryptophan / Q000008:administration & dosage*
D012701:Serotonin; D014364:Tryptophan; D011388:Prolactin; D013006:Growth Hormone; D002997:Clomipramine